News
NICE recommends tenofovir disoproxil fumarate
Posted: 3 August 2009
NICE has issued a positive recommendation for the use of tenofovir disoproxil fumarate as a treatment for compensated chronic hepatitis B (CHB) in adults.1 The drug has already been recommended following health technology assessments in Scotland and Wales.
The NICE technology appraisal states, ‘Tenofovir disoproxil, within its marketing authorisation, is recommended as an option for the treatment of people with HBeAgpositive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated’.1
1. National Institute for Health and Clinical Excellence. Single Technology Appraisal TA173, July 2009: Tenofovir disoproxil for the treatment of chronic hepatitis B.
www.nice.org.uk